Appeal and Interference Statistics
Patent Trial and Appeal Board
May 2017
Pending Appeals
(FY10 to FY17: 10/1/09 to 5/31/17)
### Pendency of Decided Appeals in FY16 and FY17
(5/31/16 compared to 5/31/17)

<table>
<thead>
<tr>
<th>Technology</th>
<th>FY16</th>
<th>FY17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio / Pharma</td>
<td>19.6</td>
<td>18.2</td>
</tr>
<tr>
<td>Chemical</td>
<td>23.5</td>
<td>26.2</td>
</tr>
<tr>
<td>Electrical / Computer</td>
<td>25.8</td>
<td>25.8</td>
</tr>
<tr>
<td>Design</td>
<td>24.8</td>
<td>22.3</td>
</tr>
<tr>
<td>Mechanical / Business Method</td>
<td>29.8</td>
<td>30.8</td>
</tr>
<tr>
<td>Overall</td>
<td>29.3</td>
<td>25.0</td>
</tr>
</tbody>
</table>

Pendency is calculated as average months from Board receipt date to final decision.

*CRU (Central Reexamination Unit) includes ex parte reexams, inter partes reexams, supplemental examination reviews and reissues from all technologies.
Appeal Intake in FY17
(10/1/16 to 5/31/17)

*The Central Reexamination Unit includes ex parte reexams, inter partes reexams, supplemental examination reviews and reissues from all technologies.
Appeal Outcomes in FY17
(FY17: 10/1/16 to 5/31/17)

- Affirmed: 55.8%
- Affirmed-in-Part: 12.5%
- Reversed: 29.9%
- Administrative and Panel Remands: 0.6%
- Dismissed: 1.2%
Interference Inventory
(FY08 to FY17: 10/1/07 to 5/31/17)